A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Enlon Overdose, Contraindications and Information - Edrophonium (injection)
Enlon Overdose, Contraindications and Information - Edrophonium (injection)
OVERDOSE
With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea,
sweating, increased bronchial and salivary secretions and bradycardia)
often appear with overdosage (cholinergic crisis). An important complication
that can arise is obstruction of the airway by bronchial secretions. These
may be managed with suction (especially if tracheostomy has been performed)
and by the use of atropine. Many experts have advocated a wide range of
dosages of atropine (for Enlon®, see atropine dosage below),
but if there are copious secretions, up to 1.2 mg intravenously may be
given initially and repeated every 20 minutes until secretions are controlled.
Signs of atropine overdosage such as dry mouth, flush and tachycardia
should be avoided as tenacious secretions and bronchial plugs may form.
A total dose of atropine of 5 to 10 mg or even more may be required. The
following steps should be taken in the management of overdosage of Enlon®:
1. Adequate respiratory exchange should be maintained by assuring an
open airway and by the use of assisted respiration augmented by oxygen.
2. Cardiac function should be monitored until complete stabilization
has been achieved.
3. Atropine sulfate in doses of 0.4 to 0.5 mg should be administered
intravenously. This may be repeated every 3 to 10 minutes. Because of
the short duration of action of Enlon® the total dose required
will seldom exceed 2 mg.
4. Pralidoxime chloride (a cholinesterase reactivator) may be given intravenously
at the rate of 50 to 100 mg per minute; usually the total dose does not
exceed 1000 mg. Extreme caution should be exercised in the use of pralidoxime
chloride when the cholinergic symptoms are induced by double-bond phosphorous
anticholinesterase drugs.9
5. If convulsions occur or shock is present, appropriate measures should
be instituted.
CONTRAINDICATIONS
Known hypersensitivity to anticholinesterase agents; intestinal and urinary
obstructions of mechanical type.
top
